<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030147</url>
  </required_header>
  <id_info>
    <org_study_id>020120</org_study_id>
    <secondary_id>ZIAMH002537-26</secondary_id>
    <secondary_id>02-M-0120</secondary_id>
    <nct_id>NCT00030147</nct_id>
  </id_info>
  <brief_title>Raloxifene and Rimostil for Perimenopause-Related Depression</brief_title>
  <official_title>The Efficacy of Phytoestrogens and Selective Estrogen Receptor Modulators in Perimenopause-Related Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of the drugs raloxifene and
      rimostil in treating perimenopause-related depression.

      Perimenopause-related mood disorders cause significant distress to a large number of women;
      the demand for effective therapies to treat these mood disorders is considerable. Estradiol
      replacement therapy (ERT) has demonstrated efficacy in treating perimenopause-related
      depression. Unfortunately, there are long-term risks associated with ERT. Selective estrogen
      receptor modulators (SERMS), such as raloxifene, and phytoestrogens, such as rimostil, have
      estrogen-like properties and may offer a safer alternative to ERT. The effect of SERMS and
      phytoestrogens on mood and cognitive functioning need to be examined in women with
      perimenopause-related depression.

      Participants in this study will undergo a medical history, physical examination,
      electrocardiogram (EKG), and blood and urine tests. They will then be randomly assigned to
      receive one of four treatments for 8 weeks: raloxifene pills plus a placebo (an inactive
      substance) skin patch, rimostil pills plus placebo skin patch, estradiol skin patch plus
      placebo pills, or placebo patch plus placebo pills. Participants will have clinic visits
      every 2 weeks. During the visits, blood will be drawn and participants will meet with staff
      members and complete symptom self-rating scales. A urine and blood sample will be collected
      at the beginning and end of the study. At the end of the study, participants who received
      placebo or whose study medication was ineffective will be offered treatment with standard
      antidepressant medications for 8 weeks. Non-menstruating women will receive progesterone for
      10 days to induce menstrual bleeding and shedding of the inner layer of the uterus, which may
      have been stimulated by the study medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perimenopause-related mood disorders cause significant distress to a potentially large number
      of women. The demand for effective therapeutic alternatives to estrogen for treating these
      mood disorders is considerable, as is the need to define clinical or biologic markers that
      may predict successful response of mood disturbances to phytoestrogens or selective estrogen
      receptor modulators (SERMs). Further, the study of potential biological mechanisms underlying
      both perimenopause-related mood disorders and their response to treatment may offer the
      possibility of uncovering some etiopathogenic mechanisms involved in these and related mood
      disorders.

      Results of protocol # 90-M-0077 demonstrated the therapeutic efficacy of estradiol therapy
      (ET) in perimenopausal depression, independent of its effects on vasomotor symptoms.
      Nevertheless, the long term risks of ET to endometrial and breast tissues continue to deter
      many women from its use. Recently, selective estrogen receptor modulators (SERMs) and
      phytoestrogens (plant-derived estrogen-like compounds) have become available and are reported
      to display both tissue-specific profiles of estrogen agonist and antagonist actions and
      differential affinities for the two forms of estrogen receptor. For many women, these novel
      compounds would represent a safer alternative to ET for the prevention of osteoporosis and
      the treatment of menopausal symptoms. However, the effects of SERMs and phytoestrogens on
      mood and cognitive function in perimenopausal women remain undetermined.

      In this protocol we wish both to investigate the effects of SERMs and phytoestrogens on mood
      and cognition under placebo controlled conditions and to compare these effects with estradiol
      therapy. This protocol will address the following questions: 1) Do selective estrogen
      receptor modulators or phytoestrogens improve mood and cognition in perimenopausal depressed
      women? 2) Are the mood and cognitive effects of SERMs and phytoestrogens comparable to those
      of ET? and 3) Do selective estrogen receptor modulators and phytoestrogens improve measures
      of bone metabolism in perimenopausal depressed women?
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Center for Epidemiologic Studies-Depression Scale (CES-D)</measure>
    <time_frame>Baseline</time_frame>
    <description>Center for Epidemiologic Studies-Depression Scale (CES-D) cutoff scores are typically used as a screen to identify clinically significant depression; a cutoff score of greater than 16 has been shown to correlate with clinically significant depression. In addition, a score between 8 and 15 has been used to define subsyndromal depression. The possible range of scores is zero to 60, with the higher scores indicating more symptoms, weighted by frequency of occurrence during the past week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Center for Epidemiologic Studies-Depression Scale (CES-D)</measure>
    <time_frame>Week 8</time_frame>
    <description>Center for Epidemiologic Studies-Depression Scale (CES-D) cutoff scores are typically used as a screen to identify clinically significant depression; a cutoff score of greater than 16 has been shown to correlate with clinically significant depression. In addition, a score between 8 and 15 has been used to define subsyndromal depression. The possible range of scores is zero to 60, with the higher scores indicating more symptoms, weighted by frequency of occurrence during the past week.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Perimenopausal Depression</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Raloxifene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raloxifene (Evista) 60 mg per day and placebo skin patch for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rimostil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rimostil (phytoestrogen) 1000 mg twice a day and placebo skin patch for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transdermal estradiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>17-beta estradiol 100 micrograms a day by skin patch and placebo tablets for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo skin patch and placebo tablets for eight weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raloxifene</intervention_name>
    <description>60 mg a day orally administered</description>
    <arm_group_label>Raloxifene</arm_group_label>
    <other_name>Evista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimostil</intervention_name>
    <description>1000 mg twice a day administered orally</description>
    <arm_group_label>Rimostil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal Estradiol</intervention_name>
    <description>100 microgram per day transdermal estradiol</description>
    <arm_group_label>Transdermal estradiol</arm_group_label>
    <other_name>Alora</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo skin patch and placebo tablets</intervention_name>
    <description>matched placebo skin patch to transdermal estradiol and matched tablets to either Raloxifene or Rimostil</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Subjects for this study will meet the following criteria:

          1. Self-report of the onset of depression associated with menstrual cycle irregularity or
             amenorrhea;

          2. A current episode of minor (meeting 3-4 criterion symptoms) or major depression (of
             moderate severity or less on the Structured Clinical Interview for Diagnostic and
             Statistical Manual of Mental Disorders (DSM)-IV (SCID) severity scale and not meeting
             DSM-IV criteria symptom 9 (suicide)) as determined by the administration of the minor
             depression module of the Schedule for Affective Disorders and Schizophrenia - Lifetime
             Version (SADS-L). Additionally, to ensure that subjects meet a minimum threshold for
             severity of depression, subjects will have scores greater than or equal to 10 on
             either the Beck Depression Inventory (BDI) or the Center for Epidemiologic Studies -
             Depression (CES-D) Scale during at least three of the four clinic visits during the
             two month screening phase, as well as a 17 item Hamilton Depression score greater than
             or equal to 10. Subjects will be excluded if they meet any of the following criteria:
             major depression of greater than moderate severity, DSM-IV criteria # 9 (suicide), or
             anyone requiring immediate treatment after clinical assessment or functional
             impairment ratings of five or six for more than seven consecutive days on daily
             ratings;

          3. Evidence of perimenopausal reproductive status;

          4. Age 40 to 60;

          5. No prior hormonal therapy for the treatment of perimenopause-related mood or physical
             symptoms within the last six months;

          6. No history of psychiatric illness during the two years prior to the reported onset of
             the current episode of depression;

          7. In good medical health, and not taking any medication or dietary and herbal
             supplements on a regular basis (with the exception of multivitamins and calcium
             supplements).

        EXCLUSION CRITERIA:

        The following conditions will constitute contraindications to treatment and will preclude a
        subject s participation in this protocol:

        1) Severe major depression with any of the following:

          1. positive (threshold) response to SCID major depression section item # 9, suicidal
             ideation;

          2. anyone requiring immediate treatment after clinical assessment;

          3. severity ratings greater than moderate on the SCID IV interview;

          4. functional impairment ratings of five or six for more than seven consecutive days on
             daily ratings.

        2) Current treatment with antidepressant medications. Our main concern is to exclude
        subjects taking medications that would treat or precipitate depression or adversely
        interact with reproductive hormones, phytoestrogens (e.g., anticoagulants), or SERMs. Thus,
        we wish to exclude only women receiving psychotropic medications, medications that have
        been reported to induce a change in mood or behavior, hormone replacement therapy, oral
        contraceptive agents, or medications that may have a potential adverse interaction with the
        compounds employed in this study.

        3) History of psychiatric illness during the two years before the reported onset of the
        current episode of depression.

        4) History of ischemic cardiac disease, pulmonary embolism, retinal thrombosis, or
        thrombophlebitis; any subject with risk factors for thrombo-embolic phenomena including
        cigarette smokers; varicose veins, patients with prolonged periods of immobilization
        (including prolonged travel), and active heart disease. The literature suggests that
        although both smoking and hormone replacement/oral contraceptives have associated risks of
        thromboembolic phenomena and cardiovascular events, these individual risks do not become
        significantly greater when combined until greater than 10 cigarettes a day are consumed.
        Thus we wish to exclude only subjects for this study who smoke greater than 10 cigarettes
        per day.

        5) Renal disease, asthma.

        6) Hepatic dysfunction.

        7) Women with a history of carcinoma of the breast, or any women with a family history of
        the following: premenopausal breast cancer or bilateral breast cancer in a first degree
        relative; multiple family members (greater than three relatives) with postmenopausal breast
        cancer.

        8) Women with a history of uterine cancer, endometriosis, ill-defined pelvic lesions,
        particularly undiagnosed ovarian enlargement, undiagnosed vaginal bleeding.

        9) Patients with a known hypersensitivity to raloxifene, phytoestrogens (including
        Rimostil, isoflavones, genistein, daidzein, red clover extract and soy-related compounds),
        estradiol, Alora, medroxyprogesterone acetate, or the excipients (inactive compounds)
        contained within these medications including: Rimostil -tocopherols, cellulose, calcium
        hydrogen phosphate, magnesium stearate, silica-colloidal anhydrous; Provera - calcium
        stearate, corn starch, lactose, mineral oil, sorbic acid, sucrose, talc; Alora - sorbitan
        monooleate, acrylic adhesive; Evista - anhydrous lactose, carnauba wax, crospovidone,
        Federal Food, Drug, and Cosmetic Act (FD&amp; C) blue # 2 aluminum lake, hydroxypropyl
        methylcellulose, lactose monohydrate, magnesium stearate, modified pharmaceutical glaze,
        polyethylene glycol, polysorbate 80, povidone, and titanium dioxide.

        10) Pregnant women.

        11) Porphyria.

        12) Diabetes mellitus.

        13) Cholecystitis or pancreatitis.

        14) History of cerebrovascular disease (stroke), epilepsy, hypertension, hypercalcemia.

        15) Recurrent migraine headaches.

        16) Malignant melanoma.

        17) History of familial hyperlipoproteinemia.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J Schmidt, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health (NIMH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2002-M-0120.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2002</study_first_submitted>
  <study_first_submitted_qc>February 6, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2002</study_first_posted>
  <results_first_submitted>June 2, 2016</results_first_submitted>
  <results_first_submitted_qc>July 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2016</results_first_posted>
  <last_update_submitted>July 18, 2016</last_update_submitted>
  <last_update_submitted_qc>July 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gonadal Steroids</keyword>
  <keyword>Estrogen Receptor</keyword>
  <keyword>Mood Disorders</keyword>
  <keyword>Perimenopause</keyword>
  <keyword>Estradiol</keyword>
  <keyword>Depression</keyword>
  <keyword>Estrogen Response Element</keyword>
  <keyword>Perimenopausal</keyword>
  <keyword>Perimenopausal Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Raloxifene Hydrochloride</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Selective Estrogen Receptor Modulators</mesh_term>
    <mesh_term>Estrogen Receptor Modulators</mesh_term>
    <mesh_term>Phytoestrogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two participants signed the consent but were not started (did not meet inclusion criteria.)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Estradiol</title>
          <description>Transdermal estradiol 17-beta estradiol 100 micrograms a day by skin patch and placebo tablets for eight weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo skin patch and placebo tablets for eight weeks</description>
        </group>
        <group group_id="P3">
          <title>Raloxifene</title>
          <description>Raloxifene (Evista) 60 mg per day and placebo skin patch for eight weeks</description>
        </group>
        <group group_id="P4">
          <title>Rimostil</title>
          <description>Rimostil (phytoestrogen) 1000mg twice a day and placebo skin patch for eight weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Estradiol</title>
          <description>Transdermal estradiol 17-beta estradiol 100 micrograms a day by skin patch and placebo tablets for eight weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo skin patch and placebo tablets for eight weeks</description>
        </group>
        <group group_id="B3">
          <title>Raloxifene</title>
          <description>Raloxifene (Evista) 60 mg per day and placebo skin patch for eight weeks</description>
        </group>
        <group group_id="B4">
          <title>Rimostil</title>
          <description>Rimostil (phytoestrogen) 1000mg twice a day and placebo skin patch for eight weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Center for Epidemiologic Studies–Depression Scale (CES-D)</title>
        <description>Center for Epidemiologic Studies–Depression Scale (CES-D) cutoff scores are typically used as a screen to identify clinically significant depression; a cutoff score of greater than 16 has been shown to correlate with clinically significant depression. In addition, a score between 8 and 15 has been used to define subsyndromal depression. The possible range of scores is zero to 60, with the higher scores indicating more symptoms, weighted by frequency of occurrence during the past week.</description>
        <time_frame>Baseline</time_frame>
        <population>The analyses included those subjects who started the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Estradiol</title>
            <description>Transdermal estradiol 17-beta estradiol 100 micrograms a day by skin patch and placebo tablets for eight weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo skin patch and placebo tablets for eight weeks</description>
          </group>
          <group group_id="O3">
            <title>Raloxifene</title>
            <description>Raloxifene (Evista) 60 mg per day and placebo skin patch for eight weeks</description>
          </group>
          <group group_id="O4">
            <title>Rimostil</title>
            <description>Rimostil (phytoestrogen) 1000mg twice a day and placebo skin patch for eight weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Center for Epidemiologic Studies–Depression Scale (CES-D)</title>
          <description>Center for Epidemiologic Studies–Depression Scale (CES-D) cutoff scores are typically used as a screen to identify clinically significant depression; a cutoff score of greater than 16 has been shown to correlate with clinically significant depression. In addition, a score between 8 and 15 has been used to define subsyndromal depression. The possible range of scores is zero to 60, with the higher scores indicating more symptoms, weighted by frequency of occurrence during the past week.</description>
          <population>The analyses included those subjects who started the study.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" spread="5.76"/>
                    <measurement group_id="O2" value="29.1" spread="9"/>
                    <measurement group_id="O3" value="28.8" spread="7.9"/>
                    <measurement group_id="O4" value="24.6" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Center for Epidemiologic Studies–Depression Scale (CES-D)</title>
        <description>Center for Epidemiologic Studies–Depression Scale (CES-D) cutoff scores are typically used as a screen to identify clinically significant depression; a cutoff score of greater than 16 has been shown to correlate with clinically significant depression. In addition, a score between 8 and 15 has been used to define subsyndromal depression. The possible range of scores is zero to 60, with the higher scores indicating more symptoms, weighted by frequency of occurrence during the past week.</description>
        <time_frame>Week 8</time_frame>
        <population>The analyses included those subjects who completed eight weeks of study</population>
        <group_list>
          <group group_id="O1">
            <title>Estradiol</title>
            <description>Transdermal estradiol 17-beta estradiol 100 micrograms a day by skin patch and placebo tablets for eight weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo skin patch and placebo tablets for eight weeks</description>
          </group>
          <group group_id="O3">
            <title>Raloxifene</title>
            <description>Raloxifene (Evista) 60 mg per day and placebo skin patch for eight weeks</description>
          </group>
          <group group_id="O4">
            <title>Rimostil</title>
            <description>Rimostil (phytoestrogen) 1000mg twice a day and placebo skin patch for eight weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Center for Epidemiologic Studies–Depression Scale (CES-D)</title>
          <description>Center for Epidemiologic Studies–Depression Scale (CES-D) cutoff scores are typically used as a screen to identify clinically significant depression; a cutoff score of greater than 16 has been shown to correlate with clinically significant depression. In addition, a score between 8 and 15 has been used to define subsyndromal depression. The possible range of scores is zero to 60, with the higher scores indicating more symptoms, weighted by frequency of occurrence during the past week.</description>
          <population>The analyses included those subjects who completed eight weeks of study</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="9.4"/>
                    <measurement group_id="O2" value="10.5" spread="11.3"/>
                    <measurement group_id="O3" value="15.8" spread="8.9"/>
                    <measurement group_id="O4" value="16.1" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Estradiol</title>
          <description>Transdermal estradiol 17-beta estradiol 100 micrograms a day by skin patch and placebo tablets for eight weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo skin patch and placebo tablets for eight weeks</description>
        </group>
        <group group_id="E3">
          <title>Raloxifene</title>
          <description>Raloxifene (Evista) 60 mg per day and placebo skin patch for eight weeks</description>
        </group>
        <group group_id="E4">
          <title>Rimostil</title>
          <description>Rimostil (phytoestrogen) 1000mg twice a day and placebo skin patch for eight weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Two participants signed the consent but were not started (did not meet inclusion criteria.) Early termination of Rimostil treatment arm limits the generalizability of treatment response in this arm.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Schmidt, Peter</name_or_title>
      <organization>National Institute of Mental Health</organization>
      <phone>+1 301 496 6120</phone>
      <email>peterschmidt@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

